Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BPR-30221616 in Healthy Subjects
NCT06760455Phase 1Recruiting
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BPR-30221616 in transthyretin amyloidosis (ATTR), sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Participants With Adverse Events (AE), Incidence of Participants With Serious Adverse Events (SAE) and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
BPR-30221616
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06760455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760455.